

**SEARCH REQUEST FORM**

Scientific and Technical Information Center

Requester's Full Name: \_\_\_\_\_ Examiner #: \_\_\_\_\_ Date: \_\_\_\_\_  
 Art Unit: \_\_\_\_\_ Phone Number 30 \_\_\_\_\_ Serial Number: \_\_\_\_\_  
 Mail Box and Bldg/Room Location: \_\_\_\_\_ Results Format Preferred (circle): PAPER DISK E-MAIL

**If more than one search is submitted, please prioritize searches in order of need.**

\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: \_\_\_\_\_

*\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Jan Delaval  
 Reference Librarian  
 Biotechnology & Chemical Library  
 CM1 1E07 - 703-308-4498  
 jan.delaval@uspto.gov

\*\*\*\*\*  
**STAFF USE ONLY**

	Type of Search	Vendors and cost where applicable
Searcher _____	NA Sequence (#) _____	STN _____
Searcher Phone # _____	AA Sequence (#) _____ <input checked="" type="checkbox"/>	Dialog _____
Searcher Location _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr Link _____
Date Completed: _____	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time _____	Fulltext _____	Sequence Systems _____ <input checked="" type="checkbox"/>
Clerical Prep Time _____	Patent Family _____	WWW/Internet _____
Online Time: _____	Other _____	Other (specify) _____

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SS3PTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Jan 23 BLAST(R) searching in REGISTRY available in STN on the Web  
NEWS 3 Jan 23 FSTA has been reloaded and moves to weekly updates  
NEWS 4 Feb 1 DRILIT now produced by FIZ Karlsruhe and has a new update frequency  
NEWS 5 Feb 13 Access via Tymnet and SprintNet Eliminated Effective 3/31/02  
NEWS 6 Mar 05 Gene Names now available in BIOSIS  
NEWS 7 Mar 11 TOXLIT no longer available  
NEWS 8 Mar 11 TROTHERM0 no longer available  
NEWS 9 Mar 13 US Provisional Priorities searched with P in CA/CAPLUS and USPATEFULL  
NEWS 10 Mar 23 LIPINSKI/CALC added for property searching in REGISTRY  
NEWS 11 Apr 01 PAPERCHEM no longer available in STN. Use PAPERCHEM2 instead.  
NEWS 12 Apr 01 "Ask CAS" for self-help around the clock  
NEWS 13 Apr 02 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 14 Apr 02 ZDB will be removed from STN  
NEWS 15 Apr 13 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 16 Apr 13 Records from IB.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 17 Apr 13 BIOSIS Gene Names now available in TOXCENTER  
NEWS 18 Apr 13 Federal Research in Progress (FEDRIP) now available  
NEWS 19 Jun 03 New e-mail delivery for search results now available  
NEWS 20 Jun 13 MEDLINE Reload  
NEWS 21 Jun 13 PCTFULL has been reloaded  
NEWS 22 Jul 01 FOREGE no longer contains STANDARDS file segment  
  
NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news in that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:05:27 ON 15 JUL 2002

=> file medline embase biosis scisearch caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 15:05:39 ON 15 JUL 2002

FILE 'EMBASE' ENTERED AT 15:05:39 ON 15 JUL 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:05:39 ON 15 JUL 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'SCISEARCH' ENTERED AT 15:05:39 ON 15 JUL 2002  
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 15:05:39 ON 15 JUL 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s "p34 human acrosomal sperm protein"

3 FILES SEARCHED...

L1 0 "P34 HUMAN ACROSOMAL SPERM PROTEIN"

=> s acrosomal sperm protein

L2 20 ACROSOMAL SPERM PROTEIN

=> s L2 and human

MISSING OPERATOR L2 AND

The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> s L2 and human

3 FILES SEARCHED...

L3 6 L2 AND HUMAN

=> s L3 and p34

L4 1 L3 AND P34

=> d L4 skip aks

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

1999:748171 Document No. 131:347079 **Acrosomal sperm  
protein** P34H antigenic fragments and use in immun contraception  
and as a marker of fertility. Sullivan, Robert; Berube, Bruno; Legare,  
Christine; Gaudreault, Christian (Immunon Inc., Can.). U.S. US 5989549 A  
19991123, 19 pp. (English). CODEN: USXXAM. APPLICATION: US 1998-90567  
19980635.

AB The present invention relates to the use of **acrosomal  
sperm protein** in immun contraception of male and female  
subjects and uses thereof as a marker for fertility. The method of  
immun contraception comprises administering to said male or female subject  
an antigenic fragment of **human acrosomal sperm  
protein P34**. Preferred antigenic fragment includes,  
without limitation, MELFLAGEEVC GR CSQDYAEPNPTWQV. An immun contraceptive  
vaccine for male or a female subject is also claimed.

=> dup remove L3

PROCESSING COMPLETED FOR L3

L5 2 DUP REMOVE L3 (5 DUPLICATES REMOVED)

=> d 15 1-3 chik ats

L5 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC. DUPLICATE 1  
2000:233398 Document No.: PREV30000233398. **Acrosomal sperm**

**protein** and uses thereof. Sullivan, Robert (1); Berube, Bruno;  
Legare, Christine; Gaudreault, Christian. (1) Quebec Canada. ASSIGNEE:  
Immucor Inc., Montreal, Canada. Patent Info.: US 5989543 November 23,  
1999. Official Gazette of the United States Patent and Trademark Office  
Patents, (Nov. 23, 1999) Vol. 122, No. 4, pp. No pagination. e-file.  
ISSN: 0098-1136. Language: English.

AB The present invention relates to the use of **acrosomal sperm protein** in immuncontraception of male and female subjects and uses thereof as a marker for fertility.

L5 ANSWER 2 OF 3 MEDLINE DUPLICATE 2

19980:4094 Document Number: 28984094. PubMed ID: 2898461. Oviductal  
antibody response to a defined recombinant sperm antigen in macaques. Kurth  
B E; Weston C; Reddi P P; Bryant D; Bhattacharya R; Flickinger C C; Herr J  
C. (Center for Recombinant Gamete Contraceptive Vaccinogens, Department of  
Cell Biology, The University of Virginia, Charlottesville 22908, USA.)  
BIOLOGY OF REPRODUCTION, (1997 Nov 57 (5) 981-9. Journal code: 0247224.  
ISSN: 0006-3361. Pub. country: United States. Language: English.

AB Macaque oviductal fluids were assayed for specific antibodies to the  
intra-**acrosomal sperm protein** SP-10 after  
immunizations with recombinant macaque SP-10 (re-mqSP-10), a candidate  
contraceptive vaccinogen. Access ports, consisting of a subcutaneous  
collecting reservoir and a catheter to cannulate the oviduct, were  
implanted into monkeys for repeated aspiration of oviductal fluid. Monkeys  
were inoculated i.m. once a month with an emulsion consisting of 2 mg  
re-mqSP-10 in a vehicle of squalene and mannin monoleate. Oviductal  
fluids and serum were collected during the periovulatory period for six  
menstrual cycles, and IgG and IgA antigen-specific antibodies in pre-immune  
and immune fluids were compared by ELISA. Both relative and absolute  
concentrations of SP-10-specific immunoglobulins (Ig) were determined.  
Oviductal fluids from immunized animals showed significant increases in  
anti-SP-10 IgG at cycle 2 and at all subsequent intervals. Anti-SP-10 IgA  
significantly increased in oviductal fluid at cycles 4, 5, and 6. Serum  
anti-SP-10 IgG increased at cycle 2 and remained significantly elevated  
through cycle 6, while serum anti-SP-10 IgA was higher than in preimmune  
samples at cycle 4. Serum antibodies generated to the recombinant SP-10  
recognized SP-10 extracted from macaque sperm in Western blots.  
Immunocytochemical staining of macaque and **human** sperm showed  
acrosomal immunofluorescence with both immune oviductal fluids and serum  
using both anti-IgG and anti-IgA secondary antibodies. This study  
demonstrates for the first time 1) IgG and IgA antibodies to a defined  
recombinant sperm-specific antigen in primate oviductal fluids after  
systemic immunization and 2) the recognition by primate oviductal fluid  
IgG and IgA of the endogenous contraceptive target in both **human**  
and macaque sperm.

L5 ANSWER 3 OF 3 SCISEARCH COPYRIGHT 2002 ISI (R)

97:74927 The Genuine Article (R Number: X0317. Monoclonal antibodies to  
canine intra-**acrosomal sperm proteins**  
recognizing acrosomal status during capacitation and acrosome reaction.  
Geussova G; Peknicova J (Reprint); Capkova J; Kalak P; Moos J;  
Philimonenko V V; Hrizak E. ACAD SCI CZECH REPUBL, INST MOL GENET, LAB BIOL  
& BIOCHEM FERTILIZAT, VIDENSKA 1983, CR-14220 PRAGUE, CZECH REPUBLIC  
(Reprint); ACAD SCI CZECH REPUBL, INST MOL GENET, LAB BIOL & BIOCHEM  
FERTILIZAT, CR-14220 PRAGUE, CZECH REPUBLIC; ACAD SCI CZECH REPUBL, INST  
ANIM PHYSIOL & GENET, DEPT GENET, CR-27721 LIBECHOV, CZECH REPUBLIC; ACAD  
SCI CZECH REPUBL, INST EXPT MED, DEPT CELL ULTRASTRUCT & MOL BIOL,

CE-14220 PRAGUE, CZECH REPUBLIC. ANDROLOGIA (SEP-OCT 1997) Vol. 23, No. 5, pp. 361-368. Publisher: BLACKWELL WISSENSCHAFTS-VERLAG GMBH. KURFURSTENDAM M 57, D-10707 BERLIN, GERMANY. ISSN: 0303-4569. Pub. country: CZECH REPUBLIC. Language: English.

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB Monoclonal antibodies Ds-1 and Ds-2 specifically labelling dog sperm acrosome were prepared by immunization of mice with acetic acid extracts of dog spermatozoa. Electron microscopy and indirect immunofluorescence localized the site of Ds-1 and Ds-2 proteins inside the acrosomal vesicle. Ds-1 antibody detected 55, 70, 115, 121 and 190 kDa proteins under nonreducing conditions, and 73 kDa and 94 kDa proteins after reduction (p73 Ds-1 and p94 Ds-1). 30 kDa and 40 kDa proteins recognized by Ds-2 (p30 Ds-2 and p40 Ds-2) migrated at > 200 kDa in the absence of reducing agent. In vivo, p73 Ds-1 and p94 Ds-1 are therefore likely to be present both in free and complexed form, while all of p30 Ds-2 and p40 Ds-2 form disulfide-bonded complexes. Decrease in the rate of acrosomes stained with Ds-1 and Ds-2 was correlated with the progress of capacitation resulting in the increased rate of spontaneous acrosome reactions, as suggested by a dramatic effect of A23187. Monoclonal antibody to boar acrosin (ACR-2) recognized dog sperm acrosin homologue. A higher rate of ACR-2-negative spermatozoa was observed after capacitation and A23187 treatment compared to Ds-1 and Ds-2, indicating that proteins recognized by Ds-1 and Ds-2 are localized in a specific compartment of acrosome, distinct from acrosin and possibly representing fraction of acrosomal matrix.

=> s "MELFLAGEPVL"

L9 : "MELFLAGEPVL"

=> s "CHKAKTMLNRI"

L7 : "CHKAKTMLNRI"

=> s immuncontraception

L8 : IMMUNOCONTRACEPTION

=> s 18 and acrosomal protein

L9 : L9 AND ACROSOMAL PROTEIN

=> dup remove L9

PROCESSING COMPLETED FOR L9

L10 : L9 DUP REMOVE L9 (4 DUPLICATES REMOVED)

=> d 110 1-2 318 abs

L10 ANSWER 1 OF 2 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V. DUPLICATE 1

2001324310 EMBASE Differential extraction and enrichment of human sperm surface proteins in a proteome: Identification of immuncontraceptive candidates. Shetty J.; Diekman A.B.; Jayes F.C.L.; Sherman N.E.; Naaby-Hansen S.; Flickinger C.J.; Herr J.D.; Dr. J.C. Herr, Department of Cell Biology, University of Virginia, Charlottesville, VA 22908-0712, United States. jchcr@virginia.edu. Electrophoresis 22/14 (3153-3066) 2001.

Refs: 43.

ISSN: 0173-0835. CODEN: ELCTDN. Pub. Country: Germany. Language: English.

Summary language: English.

AB The objective of this study was to discover previously unknown human sperm surface proteins that may be candidate contraceptive vaccingens. To this end, methods of concentrating human sperm proteins for microsequencing by mass spectrometry were used, which increased the likelihood of identifying surface proteins. Vectorial labeling, differential extraction and two-dimensional (2-D) gel electrophoresis were employed to identify and isolate proteins accessible at the cell surface. Percoll harvested or swim-up sperm were either solubilized directly or solubilized after

surface labeling with sulfo-succinimidyl-6-(biotinamido)hexanoate (sulfo-NHS-LC-biotin). Comparisons were made of proteins extracted with four lysis buffers: (i) Celis buffer containing 2.5 M urea and 1% Igepal CA-630; (ii) 1% Triton X (TX)-100; (iii) 1.7% TX-114 followed by phase partitioning; or (iv) 1 M NaCl. Blots of proteins separated by high-resolution 2-D electrophoresis were probed with avidin and antibodies to known proteins specific for three domains: the sperm surface (SAGA-1), the acrosome (SP-10), and the cytoskeleton ( $\alpha$ -tubulin). Celis buffer (45 min) extracted proteins from all three major compartments. However, a 30-s extraction in Celis buffer enriched for several proteins and enabled the identification of several novel peptides by mass spectrometry. Mild extraction with TX-100 or 1 M NaCl solubilized mainly membrane and **acrosomal proteins**, but not cytoskeletal proteins. Comparison of biotinylated proteins extracted by each method showed that the major vectorially labeled proteins solubilized by Celis buffer were also solubilized by TX-100, TX-114, and 1 M NaCl. Extraction with TX-114 followed by phase-partitioning significantly enriched hydrophobic surface proteins and aided resolution and isolation. Eight protein spots microsequenced following all these extraction methods proved to be novel sperm molecules.

L10 ANSWER 2 OF 2 MEDLINE DUPLICATE 2  
 93392979 Document Number: 93392979. PubMed ID: 8979586. Stage-specific detection of mRNA for the sperm antigen SP-10 in human testes. Kurth B E; Wright R M; Flickinger C J; Herr J C. (Department of Anatomy and Cell Biology, University of Virginia, Charlottesville 22904. ) ANATOMICAL RECORD, (1993 Aug) 236 (4) 619-25. Journal code: 0370540. ISSN: 1063-276X. Pub. country: United States. Language: English.

AB SP-10 is a sperm-specific, intra-acrosomal protein that is considered to be a vaccine candidate for **immunoneutralization**. In the present study, in situ hybridization with histin and 35S labeled riboprobes was used to determine the pattern of SP-10 mRNA expression in human testes. Both methods demonstrated SP-10 mRNA primarily in round spermatids found in stages I, II, and III of the seminiferous cycle. Morphometric analysis of silver grains with the 35S-labeled probe showed less SP-10 mRNA in spermatids at stages IV, V, and VI than in previous stages, and rarely was label found in spermatogonia or spermatocytes. The expression of SP-10 mRNA first appeared at stage I coincident with the appearance of the protein, which was shown previously to persist in the acrosomal matrix throughout spermiogenesis. The decrease in SP-10 mRNA occurred when spermatids underwent polarization, nuclear condensation, and elongation. The appearance of SP-10 mRNA in round spermatids suggests that increases in SP-10 transcription or SP-10 mRNA stability or both occur as spermatids develop from the Golgi phase to the cap phase. The subsequent decline of SP-10 mRNA, despite the persistence of the SP-10 protein in all spermatids, suggests that a decrease in SP-10 transcription or an increase in mRNA degradation occurs when spermatids elongate.

=> d his

FILE 'HOME' ENTERED AT 15:05:27 ON 15 JUL 1992

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 15:05:39 ON 15 JUL 1992

L1 0 S "P34 HUMAN ACROSOMAL SPERM PROTEIN"  
 L2 20 S ACROSOMAL SPERM PROTEIN  
 L3 8 S L1 AND HUMAN  
 L4 1 S L1 AND P34  
 L5 3 DUP REMOVE L6 (5 DUPLICATES REMOVED)  
 L6 0 S "MEFLAGEVI"  
 L7 0 S "CHKAKTMLNEI"

L8 226 S IMMUNOCONTRACEPTION  
L9 3 S L8 AND ACROSMAL PROTEIN  
L10 2 DUP REMOVE L8 (3 DUPLICATES REMOVED)

=> s 18 and "p34"

L11 1 L8 AND "P34"

=> d 111 chib abs

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

1999:748171 Document No. 181:347079 Acrosomal sperm protein P34H antigenic fragments and use in **immunocontraception** and as a marker of fertility. Sullivan, Robert; Serube, Bruno; Legare, Christine; Gaudreault, Christian (Immunicon Inc., Can.). U.S. US 5989549 A 19991123, 19 pp. (English). CODEN: USXXAM. APPLICATION: US 1999-00567 19980608.

AB The present invention relates to the use of acrosomal sperm protein in **immunocontraception** of male and female subjects and uses thereof as a marker for fertility. The method of **immunocontraception** comprises administering to said male or female subject an antigenic fragment of human acrosomal sperm protein **P34**. Preferred antigenic fragment includes, without limitation, MELFLAGRENC OR CSQDQYAEPNETWQV. An immunocontraceptive vaccine for male or a female subject is also claimed.

=> s (sullivan r1/au or serube b2/au or legare c2/au)

L12 2966 (SULLIVAN R1/AU OR SERUBE B2/AU OR LEGARE C2/AU)

=> s 112 and acrosomal protein

L13 6 L12 AND ACROSMAL PROTEIN

=> s 113 And "p34"

L14 6 L13 AND "P34"

=> s 113 and immunocontraception.

L15 6 L13 AND IMMUNOCONTRACEPTION

=> s 113 and immunocontraception.

L16 8 L13 AND IMMUNOCONTRACEPTION

=> dup remove 116

PROCESSING COMPLETED FOR L16

L17 3 DUP REMOVE L16 (5 DUPLICATES REMOVED)

=> d 117 1-3 chib abs

L17 ANSWER 1 OF 3 MEDLINE

DUPLICATE 1

2002110112 Document Number: 21657069. PubMed ID: 11866698. Effect of immunization of hamsters against recombinant P26h on fertility rates. Gaudreault C; Montfort C; Sullivan R. (Centre de Recherche en Biologie de la Reproduction and Departement d'Obstetrique-Gynecologie, Faculte de Medecine, Universite Laval, 2705 Blvd. Laurier, Ste-Foy, QC G1V 4G1, Canada.) Reproduction, (1992 Feb) 103 (2) 307-13. Journal code: 109966036. ISSN: 1479-1626. Pub. country: England: United Kingdom. Language: English.

AB Despite the various contraceptive methods available, an effective and inexpensive method remains to be established. **Immunocontraception** may help to achieve this goal. P26h has been proposed as a candidate for the development of a male contraceptive vaccine. P26h, a hamster sperm protein, interacts with the zona pellucida. Furthermore, in vivo fertilization can be blocked completely by active immunization of male hamsters against P26h. Maltose binding protein (MBP)-P26 shares antigenic determinants with the native P26h present on cauda epididymal spermatozoa.

The aim of the present study was to reproduce the immun contraceptive properties of native P26h by immunizing male hamsters against a recombinant P26h fused with a maltose binding protein (MBP). Active immunization of male hamsters with the MBP-P26h showed that specific anti-P26h circulating IgGs could be generated. Mating of immunized male hamsters with superovulated females resulted in a significant decrease, 20-25%, in the fertilization rate. This result is in agreement with results from *in vitro* sperm-zona pellucida binding assays. Indeed, the anti-recombinant P26h IgGs showed lower inhibitory properties when compared with anti-native P26h IgG. Despite the high anti-P26h IgG titres generated in hamsters, histological studies showed that active immunization has no pathological sequelae to the reproductive tissues. The potential of P26h as a candidate for a contraceptive vaccine is discussed.

L17 ANSWER 2 OF 3 BIOSIS COPYRIGHT 2000 BIOLOGICAL ABSTRACTS INC.DUPLICATE 2  
2000:288398 Document No.: PREV160000228398. Acrosomal sperm protein and uses thereof. Sullivan, Robert (1); Berube, Bruno;

Legare, Christine; Gaudreault, Christian. (1) Quebec Canada.  
ASSIGNEE: Immunon Inc., Montreal, Canada. Patent Info.: US 5969542  
November 23, 1999. Official Gazette of the United States Patent and  
Trademark Office Patents, (Nov. 23, 1999) Vol. 1223, No. 4, pp. No  
pagination. e file. ISSN: 0096-1188. Language: English.

AB The present invention relates to the use of acrosomal sperm protein in  
**immunocontraception** of male and female subjects and uses thereof  
as a marker for fertility.

L17 ANSWER 2 OF 3 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.  
96042084 EMBASE Document No.: 1996042084. [Epididymal proteins as targets for  
contraception in men and women]. LES PROTEINES EPIDIDYMAIRES EN TANT QUE  
CIBLES POUR UNE CONTRACEPTION MASCULINE ET FEMININE. Bode F.;  
Sullivan R.. Unite d'Ontogenie/Reproduction, Centre de Recherche,  
Universite Laval, 2708, Bd Laurier, Ste Foy, Que. G1V 4G1, Canada.  
References en Gynecologie Obstetrique 343 (258-265) 1995.  
ISSN: 1144-8148. CODEN: RGOFB2. Pub. Country: France. Language: French.  
Summary Language: English; French.

AB Epididymal functions consist in sperm storage and transport from testis to  
ejaculatory duct. During the epididymal transit, spermatozoa acquire their  
forward motility and fertilizing ability. The epithelium bordering the  
epididymal lumen is characterized by high absorption and secretory  
activities. Secreted proteins modify the epididymal fluid composition and  
are involved in sperm surface modifications that occurs during epididymal  
maturation. Some specific human epididymal proteins have been described  
but their function remains often unknown. FLB1 and P34H are two proteins  
added to spermatozoa during the epididymal transit in human. These  
proteins have been shown to be involved in the acquisition by the male  
gamete of its fertilizing ability. These proteins could thus be considered  
as markers of epididymal function in sperm maturation. Many sperm antigens  
have been proposed as targets for **immunocontraception**. LDH-C4,  
SP-10, MSA-63, FA-1, EH-20 and P26h are sperm proteins that have been  
successfully used to induce an immunological infertility in different  
animals species. Except P26h, these sperm antigens appear during  
spermatogenesis within seminiferous tubules. Thus, to be considered as an  
ideal target for **immunocontraception** in men and women, it is  
proposed that a sperm antigen should be added to the sperm surface during  
the epididymal transit. Furthermore, it should be unique to the male  
gamete and involved in one of the key events leading to fertilization.  
Considering their origin, localization and function, the two human sperm  
antigens, FLB1 and P34H, represents good candidates for the development of  
**immunocontraception**.



---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	66.79	67.90
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.24	-1.24

STN INTERNATIONAL LOGOFF AT 15:12:20 ON 15 JUL 2002

## WEST Search History

DATE: Monday, July 15, 2002

### Set Name Query

side by side

### Hit Count Set Name result set

*DB USPT; PLUR YES; OP OR*

L10	(robert)adj(sullivan) (christian)adj(gaudreault)	1	L10
L9	L8 and acrosomal protein	123712	L9
L8	(sullivan)adj(robert)	762	L8
L7	(robert)adj(sullivan)	1	L7
L6	5989549.pn.	1	L6
L5	(robert)adj(sullivan)same(bruno)adj(berube)same(christine)adj(legare)	0	L5
L4	(acrosomal)adj(protein)	13	L4
L3	(acrosomal)adj(protein)same(MKLNFSXLRLVTGAKGIG)	0	L3
L2	(acrosomal)adj(protein)same(p34)same(p26)	0	L2
L1	(vaccine)same(contraceptive)same(acrosomal)adj(protein)	5	L1

END OF SEARCH HISTORY